Eli Lilly and Company (LLY)vsXencor Inc (XNCR)
LLY
Eli Lilly and Company
$1,430.13
-0.70%
HEALTHCARE · Cap: $1.26T
XNCR
Xencor Inc
$38.13
-4.60%
HEALTHCARE · Cap: $3.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 43024% more annual revenue ($86.46B vs $200.49M). LLY leads profitability with a 31.9% profit margin vs -58.8%. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
XNCR
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+82.8%
Fair Value
$71.11
Current Price
$38.13
$32.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Revenue surging 454.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
0.0% earnings growth
ROE of -33.4% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : XNCR
The strongest argument for XNCR centers on Revenue Growth, Debt/Equity. Revenue growth of 454.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Bear Case : XNCR
The primary concerns for XNCR are EPS Growth, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while XNCR is a hypergrowth play — different risk/reward profiles.
XNCR carries more volatility with a beta of 0.77 — expect wider price swings.
XNCR is growing revenue faster at 454.9% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 30/100), backed by strong 31.9% margins and 38.6% revenue growth. XNCR offers better value entry with a 82.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Xencor Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?